Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
ApexOnco Front Page
Recent articles
Inclacumab fails, and osivelotor is on hold.
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
One first-in-human study and two deals in a single day sees companies blaze the ADC trail.
CuraDev and OncoNano move into phase 1, trying to avoid the negative precedent of other Sting agonist projects.
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.